15 April 2025 Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.
US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo to develop small molecule therapies targeting RNA in neurodegenerative diseases. 16 April 2025
Italian pharma major Recordati today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative. 16 April 2025
UK pharm major GSK has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in the pharmaceutical industry, the trade group’s Prescription Medicines Code of Practice Authority (PMCPA) has revealed. 16 April 2025
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Dutch specialty pharma firm Norgine Pharmaceuticals has entered into a definitive agreement to acquire Theravia, a French pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions from Mérieux Equity Partners. 16 April 2025
German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing liver regeneration. 15 April 2025
Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA. 15 April 2025
Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). 15 April 2025
Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results. 15 April 2025
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
US pharma major Bristol Myers Squibb yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos (mavacamten) did not meet its primary endpoints for treating non-obstructive hypertrophic cardiomyopathy (nHCM). 15 April 2025
Japan’s RaQualia Pharma has announced the termination of the license agreement regarding a retinoic acid receptor agonist (tamibarotene/TM-411/SY-1425, between the USA’s Syros Pharmaceuticals and TMRC Co, a consolidated subsidiary of RaQualia. 14 April 2025
US pharma giant Pfizer has announced that it is discontinuing development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. 14 April 2025
The Dutch Healthcare Authority (NZa) has published a report entitled From patent to competition – Analysis of expenditure and use of seven expensive medicines in hospital treatments. 14 April 2025
Japanese biotech Prism BioLab has entered a strategic partnership with AI drug discovery company Elix to accelerate the development of small molecule therapies for difficult-to-treat diseases. 14 April 2025
New regulations for running clinical trials in the UK have now been signed into law, the Medicines & Healthcare products Regulatory Agency (MHRA) announced on Friday. 14 April 2025
According to the country’s trade group LIF, Sweden must be a driving force in the European Union (EU) to ensure that pharmaceuticals continue to be exempt from tariffs and that a negotiated solution with the US must be reached. 14 April 2025
US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo to develop small molecule therapies targeting RNA in neurodegenerative diseases. 16 April 2025
Italian pharma major Recordati today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative. 16 April 2025
UK pharm major GSK has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in the pharmaceutical industry, the trade group’s Prescription Medicines Code of Practice Authority (PMCPA) has revealed. 16 April 2025
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Dutch specialty pharma firm Norgine Pharmaceuticals has entered into a definitive agreement to acquire Theravia, a French pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions from Mérieux Equity Partners. 16 April 2025
German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing liver regeneration. 15 April 2025
Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA. 15 April 2025
Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). 15 April 2025
Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results. 15 April 2025
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
US pharma major Bristol Myers Squibb yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos (mavacamten) did not meet its primary endpoints for treating non-obstructive hypertrophic cardiomyopathy (nHCM). 15 April 2025
Japan’s RaQualia Pharma has announced the termination of the license agreement regarding a retinoic acid receptor agonist (tamibarotene/TM-411/SY-1425, between the USA’s Syros Pharmaceuticals and TMRC Co, a consolidated subsidiary of RaQualia. 14 April 2025
US pharma giant Pfizer has announced that it is discontinuing development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. 14 April 2025
The Dutch Healthcare Authority (NZa) has published a report entitled From patent to competition – Analysis of expenditure and use of seven expensive medicines in hospital treatments. 14 April 2025
Japanese biotech Prism BioLab has entered a strategic partnership with AI drug discovery company Elix to accelerate the development of small molecule therapies for difficult-to-treat diseases. 14 April 2025
New regulations for running clinical trials in the UK have now been signed into law, the Medicines & Healthcare products Regulatory Agency (MHRA) announced on Friday. 14 April 2025
According to the country’s trade group LIF, Sweden must be a driving force in the European Union (EU) to ensure that pharmaceuticals continue to be exempt from tariffs and that a negotiated solution with the US must be reached. 14 April 2025